Disease Domain | Count |
---|---|
Nervous System Diseases | 1 |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 3 |
Biological products | 1 |
Target |
Mechanism PDE2A inhibitors |
Active Org. |
Originator Org. |
Active Indication- |
Inactive Indication- |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism MGAT modulators |
Active Org. |
Originator Org. |
Active Indication- |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism- |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date13 Nov 2017 |
Sponsor / Collaborator |
Start Date13 Sep 2017 |
Sponsor / Collaborator |
Start Date01 Feb 2016 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
DNS-003 | Cognition Disorders More | Preclinical |
DNS-8254 ( PDE2A ) | Memory Disorders More | Discovery |
DNS-3379 | Ischemic stroke More | Discontinued |
DNS-7801 | Motor Disorders More | Discontinued |
HT-3951 ( MAO-B ) | Ischemic stroke More | Discontinued |